* Selecta Biosciences Inc is expected to show a fall in quarterly revenue when it reports results
* The Watertown Massachusetts-based company is expected to report
a 46.8% decrease in revenue to $11.025 million from $20.71 million a year ago, according to the mean estimate from 6 analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Selecta Biosciences Inc is for a loss of 6 cents per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for Selecta Biosciences Inc is $4, above its last closing price of $1.23.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Jun. 30 2023 -0.08 -0.08 -0.07 Beat 12.5
Mar. 31 2023 -0.09 -0.09 -0.14 Missed -60.7
Dec. 31 2022 -0.08 -0.07 0.04 Beat 154.9
Sep. 30 2022 0.03 -0.01 -0.05 Missed -775.7
Jun. -0.06 -0.08 0.06 Beat 177.8
30 2022
Mar. 31 2022 -0.10 -0.11 0.23 Beat 312.3
Dec. 31 2021 -0.08 -0.07 0.03 Beat 141.2
Sep. 30 2021 -0.03 -0.07 -0.16 Missed -115.4
This summary was machine generated October 30 at 18:33 GMT. All figures in US dollars unless otherwise stated.
Comments